张立立 王亮

摘  要：目的  补肾解毒汤联合化疗治疗晚期肺癌骨转移患者的效果及对其血清糖类抗原125（CA125）、糖类抗原199（CA199）和细胞角蛋白19的可溶性片段（CYFRA21-1）水平的影响。方法  选取2018年6月～2020年12月平原县第一人民医院收治的78例晚期肺癌骨转移患者为研究对象，以随机抽签法分为对照组和观察组，每组39例。对照组患者仅实施化疗，观察组患者实施化疗联合补肾解毒汤治疗。比较两组的血清CA199、CA125、CYFRA21-1水平、卡氏功能状态量表（KPS）评分及视觉模拟量表（VAS）评分。结果  观察组血清CA199、CA125、CYFRA21-1水平低于对照组，差异有统计学意义（P<0.05）。治疗后，观察组KPS评分高于对照组，VAS评分低于对照组，差异有统计学意义（P<0.05）。结论  对晚期肺癌骨转移患者行化疗联合补肾解毒汤治疗，可有效降低肿瘤标志物水平，抑制癌细胞的发展，减轻患者不适感，提高生存质量。

关键词：晚期肺癌;骨转移;化疗;补肾解毒汤

中图分类号：R734.2    文献标识码：A    文章编号：1009-8011（2021）-18-0003-03

Abstract： Objective  To explore the effect of Bushen Jiedu Decoction combined with chemotherapy in the treatment of patients with advanced lung cancer bone metastasis and its effect on serum carbohydrate antigen 125（CA125）， carbohydrate antigen 199（CA199） and soluble fragments of cytokeratin 19（CYFRA21-1）. Methods  Select 78 patients with advanced lung cancer and bone metastases received in First People's Hospital of Pingyuan County from June 2018 to December 2020 as the object， and divided into a control group and an observation group by random drawing， with 39 cases in each group. The patients in the control group were treated with chemotherapy， and the patients in the observation group were treated with chemotherapy and Bushen Jiedu Decoction. The serum CA199， CA125 and CYFRA21-1 levels， KPS score， and VAS score were compared. Results  The serum levels of CA199， CA125， and CYFRA21-1 in the observation group were lower than those in the control group， and the difference was statistically significant（P<0.05）. After treatment， the KPS score of the observation group was higher than that of the control group， and the VAS score was lower than that of the control group， the difference was statistically significant（P<0.05）. Conclusion  Chemotherapy combined with Bushen Jiedu Decoction treatment for patients with advanced lung cancer bone metastases can effectively reduce the level of tumor markers， inhibit the development of cancer cells， reduce patient discomfort， and improve the quality of life.

Keywords： Advanced lung cancer; Bone metastasis; Chemotherapy; Bushen Jiedu Decoction

肺癌是臨床常见的肿瘤疾病，有35%～55%的肺癌患者存在骨转移，这不但会导致患者出现剧烈疼痛，而且会对其活动能力带来影响，尤其是对于晚期肺癌骨转移患者而言，会严重威胁其生命安全[1]。化疗是目前临床治疗此疾病的常用方法，虽然能使患者生存期延长、病灶缩小，但整体疗效往往欠佳。据报道，采用中医药治疗肺癌骨转移患者有助于改善患者的症状，提升其生存质量，降低不适感[2]。本研究旨在探究补肾解毒汤联合化疗治疗晚期肺癌骨转移患者的效果及对其血清癌抗原125（carcinoembryonic antigen 125，CA125）、血清癌抗原199（carcinoembryonic antigen 199，CA199）及细胞角蛋白19的可溶性片段（soluble fragment of cytokeratin-19，CYFAR21-1）的影响。

1  资料与方法

1.1  一般资料

选取2018年6月～2020年12月平原县第一人民医院收治的78例晚期肺癌骨转移患者为研究对象，以随机抽签法分为对照组和观察组，每组39例。对照组男22例，女17例;年龄42～70岁，平均年龄（56.42±2.15）岁;TNM分期：Ⅲb型24例，Ⅳ型15例;鳞癌13例，腺癌26例。……